MetLife, Inc.
Financial ServicesNYSE:MET · New York Stock Exchange
+$1.34 today
Vol 1.67M · Avg 3.48M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$76.9B of revenue converted into $3.6B of net income for the selected period. Gross margin is 27.9% and net margin is 4.8%, showing how much revenue survives after costs and taxes. EPS is $5.16, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.1B +10.2% | $69.9B +3.3% | $67.7B -0.4% | $68.0B +7.3% | $63.4B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $49.1B -3.7% | $50.9B +1.0% | $50.4B +2.8% | $49.0B +5.4% | $46.5B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $28.0B +47.5% | $19.0B +9.9% | $17.3B -8.7% | $18.9B +12.5% | $16.8B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 36.4% +9.2pp | 27.2% +1.6pp | 25.5% -2.3pp | 27.9% +1.3pp | 26.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $0 -100.0% | $6.0B -3.0% | $6.2B +5.4% | $5.9B +1.8% | $5.8B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $23.4B +74.7% | $13.4B -11.6% | $15.1B +20.3% | $12.6B +51.2% | $8.3B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $714.0M -0.6% | $718.0M +6.7% | $673.0M -3.0% | $694.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $5.7B -22.4% | $7.4B +87.8% | $3.9B -50.8% | $8.0B -21.3% | $10.1B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 7.4% -3.1pp | 10.5% +4.7pp | 5.8% -5.9pp | 11.7% -4.3pp | 16.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $4.7B -17.1% | $5.6B +160.0% | $2.2B -66.0% | $6.4B -25.3% | $8.5B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 6.0% -2.0pp | 8.0% +4.8pp | 3.2% -6.2pp | 9.4% -4.1pp | 13.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.1B +2.3% | $1.0B -0.8% | $1.0B +11.4% | $938.0M +2.0% | $920.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $0 | $0 | $0 | $0 | $0 | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $4.7B -17.1% | $5.6B +160.0% | $2.2B -66.0% | $6.4B -25.3% | $8.5B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 6.0% -2.0pp | 8.0% +4.8pp | 3.2% -6.2pp | 9.4% -4.1pp | 13.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.3B +6.8% | $1.2B +110.4% | $560.0M -47.3% | $1.1B -35.3% | $1.6B | $1.3B | -$1.6B | $745.2M |
| Net Income | $3.4B -23.7% | $4.4B +180.5% | $1.6B -70.1% | $5.3B -22.9% | $6.9B | $4.9B | $4.8B | $4.7B |
| Net Margin | 4.4% -1.9pp | 6.3% +4.0pp | 2.3% -5.4pp | 7.8% -3.0pp | 10.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $5 -19.7% | $6 +228.6% | $2 -71.3% | $6 -17.5% | $8 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $5 -19.2% | $6 +228.2% | $2 -71.3% | $6 -17.6% | $8 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $665.0M -3.5% | $689.2M -9.6% | $762.4M -2.1% | $779.1M -5.6% | $825.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $665.0M -6.5% | $711.1M -6.7% | $762.4M -5.7% | $808.9M -7.0% | $869.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Manulife Financial Corporation
NYSE:MFC
$67.13B
Aflac Incorporated
NYSE:AFL
$59.98B
Prudential Financial, Inc.
NYSE:PRU
$37.64B
Prudential plc
NYSE:PUK
$33.11B
Unum Group
NYSE:UNM
$14.80B
Globe Life Inc.
NYSE:GL
$12.95B
Jackson Financial Inc.
NYSE:JXN
$7.60B
Lincoln National Corporation
NYSE:LNC
$7.14B
CNO Financial Group, Inc.
NYSE:CNO
$4.70B
Brighthouse Financial, Inc.
BHFAP
$2.48B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MET generate?
MetLife, Inc. (MET) reported $77.08B of revenue in fiscal 2025.
Is MET profitable?
MetLife, Inc. (MET) reported $3.38B of net income, with a net margin of 4.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.